Background-No clinical standard currently exists for the optimal management of nausea induced by emetogenic chemotherapy, particularly delayed nausea.
In patients with breast cancer, the risk of developing chemotherapy-induced nausea and vomiting (CINV) is particularly high due to the common use of highly emetogenic chemotherapy coupled with pt-related risk factors including female gender and young age. Despite prophylactic antiemetics, controlling CINV is difficult in this high risk population, particularly in the delayed phase following CT. Palonosetron, a potent 5-HT3 receptor antagonist (RA) with a distinctly different pharmacokinetic and receptor binding profile, has demonstrated improved CINV protection compared to older 5-HT3 RAs in phase 3 and 4 clinical trials in a variety of settings and tumor types. We conducted a retrospective subset analysis of pts with breast cancer, the majority of whom (89%) received anthracycline combination chemotherapy (doxorubicin or epirubicin and cyclophosphamide, AC/EC) from four phase 3, randomized, double-blind, parallel group studies to assess the comparative effectiveness and safety of single IV doses of palonosetron (0.25 or 0.75 mg) versus older 5HT3-RAs (ondansetron 32 mg, dolasetron 100 mg, and granisetron 3 mg) in preventing CINV in pts receiving this highly emetogenic chemotherapy. The primary efficacy evaluation was for complete response (CR), defined as the proportion of patients with no emetic episodes & no use of rescue medication during 0–24hrs (acute), >24-120hrs (delayed), & 0–120hrs (overall) using a logistic regression model. A comparative descriptive safety assessment was also performed. A total of 1197 patients with breast cancer were included in this analysis (palonosetron n=714; older 5HT3-RAs n=483). Higher CR rates were seen for palonosetron vs. older 5HT3-RAs during the acute (63.4% vs 59.4%, p= 0.08), delayed (59.2% vs. 44.9%, p<0.0001) and overall (50.7% vs.38.5%, p<0.0001) phases. Rates for CR were similarly higher for palonosetron-treated patients in the large subgroup of patients receiving AC/EC based chemotherapy. Consistent improvements associated with palonosetron were seen for secondary endpoints of complete control (CR + no more than mild nausea), no emesis, and severity of nausea. The adverse event (AE) profile for palonosetron was similar to older 5HT3-RAs, with headache and constipation being the most commonly reported treatment-related AEs with similar incidences for all 5-HT3 RAs. This retrospective analysis of patients with breast cancer, including a large subgroup receiving anthracycline-based highly emetogenic chemotherapy, demonstrated significantly improved CINV prevention with palonosetron compared to older 5HT3-RAs, particularly in the delayed phase. Safety was comparable. This data has important implications for current CINV prevention guidelines. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-13-03.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.